Company / Shareholders' Equity
Bionano Genomics, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$44.4M
FY2025
5-year range
$35.1M / $249.4M
FY2021-FY2025
Trend
-53.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $249M in FY2022 to $44M in FY2025.
Based on SEC 10-K filings.
$44M in FY2025 with a 5-year CAGR of +65.2%.
Declined from $249M to $44M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -43.7%
- 5-Year CAGR
- +65.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- Bionano Genomics, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of +65.2%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 53.8% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -8.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.4M | -53.8% |
| FY2024 | $96.2M | -61.4% |
| FY2023 | $249.4M | -0.0% |
| FY2022 | $249.4M | +610.9% |
| FY2021 | $35.1M | +870.8% |
| FY2020 | $3.6M | -64.4% |
| FY2019 | $10.1M | +120.2% |
| FY2018 | -$50.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026